Inflammation in pulmonary arterial hypertension
Top Cited Papers
- 1 August 2003
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 22 (2) , 358-363
- https://doi.org/10.1183/09031936.03.00038903
Abstract
Inflammatory mechanisms appear to play a significant role in some types of pulmonary hypertension (PH), including monocrotaline-induced PH in rats and pulmonary arterial hypertension of various origins in humans, such as connective tissue diseases (scleroderma, systemic lupus erythematosus, mixed connective disease), human immunodeficiency virus infection, or plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal (M) protein and skin changes (POEMS) syndrome.Interestingly, some patients with severe pulmonary arterial hypertension associated with systemic lupus erythematosus have experienced significant improvements with immunosuppressive therapy, emphasising the relevance of inflammation in a subset of patients presenting with PH. Patients with primary PH (PPH) also have some immunological disturbances, suggesting a possible role for inflammation in the pathophysiology of this disease. A subset of PPH patients have been shown to have circulating autoantibodies, including antinuclear antibodies, as well as elevated circulating levels of the pro-infammatory cytokines, interleukins ‐1 and ‐6. Lung histology has also revealed inflammatory infiltrates in the range of plexiform lesions in patients displaying severe PPH, as well as an increased expression of the chemokines regulated upon activation, normal T‐cell expressed and secreted (RANTES) and fractalkine.Further analysis of the role of inflammatory mechanisms is necessary to understand whether this component of the disease is relevant to its pathophysiology.Keywords
This publication has 50 references indexed in Scilit:
- Early application of Met-RANTES ameliorates chronic allograft nephropathyKidney International, 2002
- Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery diseaseBlood, 2001
- Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1Published by Elsevier ,2000
- Fine Specificity of Anti‐Fibrillin‐1 Autoantibodies in Primary Pulmonary Hypertension SyndromeScandinavian Journal of Immunology, 2000
- ChemokinesImmunity, 2000
- Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1: Rapid CommunicationKidney International, 1999
- Immunosuppressant PG490 (Triptolide) Inhibits T-cell Interleukin-2 Expression at the Level of Purine-box/Nuclear Factor of Activated T-cells and NF-κB Transcriptional ActivationJournal of Biological Chemistry, 1999
- Improvement of severe pulmonary hypertension in a patient with SLE.Annals of the Rheumatic Diseases, 1996
- Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigmCell, 1994
- Pulmonary Arterial Hypertension Responsive to Immunosuppressive Therapy in Systemic Lupus ErythematosusLupus, 1993